Is Rapport Therapeutics, Inc. Common Stock (RAPP) a Buy, Sell, or Hold?
NASDAQ : RAPP
Rapport Therapeutics, Inc. Common Stock
$40.98 USD
-$1.8 (-4.21%)
- Volume
- 232.5K
- Average Volume
- 369.49K
- Market Capitalization
- $1.96B
- P/E Ratio
- -15.76
- Dividend Yield
- 0.00%
- Price Target
- $56.00
- Year High
- $44.28
- Year Low
- $13.62
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $27.08
Company Overview
NASDAQ
Abraham N. Ceesay
Biotechnology
Healthcare
RAPP
84
US
USD
Liquidity Metrics
0.02
27.08
27.08
4.36
0.00
Sales & Valuation
-$
98.00
4.11
-24.28
-1.71
Profitability
-$2.86
-$111.48M
-536.39%
-536.39%
-24.79%
-21.56%
P/E Metrics
-15.76
0.98
0.98
Analyst Price Target & Rating
$56.00
$66.00
$43.00
2/5
5 Analysts
-26.82%
Financial Health Scores
46.72
3/9
$466.8M
$497.6M
$26.08M
-$119.14M
Key Metrics (TTM)
$1.89B
94.63
-16.02
27.08
-24.79%
-25.34%
-5.54%
-4.12%
-3200 days
Company Executives
| Name | Title |
|---|---|
| Karina Chmielewski | Chief Information Officer & Head of Operations |
| David Bredt | Founder & Chief Scientific Officer |
| Kathleen A. Wilkinson | Chief People Officer |
| Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director |
| Swamy Yeleswaram | Chief Development Officer |
| Steven Paul | Founder & Independent Chairman |
| Jeffrey Sevigny | Chief Medical Officer |
| Troy A. Ignelzi | Chief Financial Officer |
| Cheryl Gault | Chief Operating Officer |
| Julie DiCarlo | Head of Communications & Investor Relations |
Poll Results
No votes yet today — be the first to share your view!
About Rapport Therapeutics, Inc. Common Stock (NASDAQ:RAPP) Stock
Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine recept ... or (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.
Analysts Set Rapport Therapeutics, Inc. (NASDAQ:RAPP) Price Target at $57.86
2026-07-18 03:29:18
Shares of Rapport Therapeutics, Inc. (NASDAQ: RAPP - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven ratings firms that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has issued a strong buy
2026-07-12 19:33:01
COO Cheryl Gault sold 10,000 shares on June 30, 2026, for a transaction value of ~$416,000, based on a weighted average price of $41.58 per share. This sale represented 6.2% of Gault's direct holdings, reducing her position from 159,914 to 149,914 shares.
2026-06-08 15:48:31
Rapport Therapeutics, Inc. (RAPP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
2026-05-20 16:05:00
BOSTON and SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today announced that management plans to participate in two upcoming investor conferences. Jefferies Global Healthcare Conference (New York City) – fireside chat on Wednesday, June 3, 2026, at 8:45 am ET.
Rapport Therapeutics, Inc. (RAPP) Reports Q1 Loss
2026-05-07 09:51:16
Rapport Therapeutics, Inc. (RAPP) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.56. This compares to a loss of $0.68 per share a year ago.
Rapport Therapeutics Reports First Quarter 2026 Financials and Provides Business Update
2026-05-07 07:00:00
Phase 2a follow-up period data for RAP-219 in focal onset seizures (FOS) demonstrated sustained seizure reduction, including a 90% median reduction in clinical seizures over baseline in weeks 9-12 RAP-219 Phase 2 trial in bipolar mania topline results now expected in the fourth quarter of 2026, ahead of previous 1H 2027 guidance RAP-219 Phase 3 program in FOS remains on track for initiation in the second quarter of 2026 Pipeline programs, including RAP-219 long-acting injectable formulation, RAP-219 in primary generalized tonic-clonic seizures, and α6β4 nAChR in chronic pain and migraine, continue to advance Strategic collaboration and license agreement entered into with Tenacia Biotechnology to develop and commercialize RAP-219 in Greater China across indications Ended the first quarter of 2026 with $476.8 million in cash, cash equivalents and short-term investments, excluding restricted cash, expected to fund operations into the second half of 2029 BOSTON and SAN DIEGO, May 07, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for patients with neurological or psychiatric disorders, today reported financial results for the quarter ending March 31, 2026, and provided a business update. “We entered 2026 with strong momentum across the RAP-219 development program, highlighted by compelling new follow-up Phase 2a data recently presented at AAN that further reinforces RAP-219's treatment effect in focal onset seizures and builds confidence as we enter our Phase 3 trials,” said Abraham N.
Frequently Asked Questions
-
What is the current Rapport Therapeutics, Inc. Common Stock (RAPP) stock price?
-
Rapport Therapeutics, Inc. Common Stock(NASDAQ:RAPP) stock price is $40.98 in the last trading session. During the trading session, RAPP stock reached the peak price of $44.28 while $13.62 was the lowest point it dropped to. The percentage change in RAPP stock occurred in the recent session was --4.21% while the dollar amount for the price change in RAPP stock was -$1.8.
-
RAPP's industry and sector of operation?
-
The NASDAQ listed RAPP is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of RAPP?
-
Karina Chmielewski | Chief Information Officer & Head of Operations
David Bredt | Founder & Chief Scientific Officer
Kathleen A. Wilkinson | Chief People Officer
Abraham N. Ceesay | Chief Executive Officer, President, Treasurer & Director
Swamy Yeleswaram | Chief Development Officer -
How many employees does RAPP have?
-
Number of RAPP employees currently stands at 84. RAPP operates from 1325 Boylston Street, Boston, MA 02110, US.
-
Link for RAPP official website?
-
Official Website of RAPP is: https://www.rapportrx.com
-
How do I contact RAPP?
-
RAPP could be contacted at phone #+1 617 945 0548 and can also be accessed through its website. RAPP operates from 1325 Boylston Street, Boston, MA 02110, US.
-
How many shares of RAPP are traded daily?
-
The average number of RAPP shares traded daily for last 3 months was 369.49K.
-
What is the market cap of RAPP currently?
-
The market value of RAPP currently stands at $1.96B with its latest stock price at $40.98